New cell therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new cell therapy (BST08) for people with advanced non-small cell lung cancer that has not improved after at least two prior treatments. The treatment is made from a sample of your own tumor, so it may be a personalized option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have non-small cell lung cancer that has not responded to at least two prior treatments, including an immunotherapy (like a PD-1 or PD-L1 inhibitor).
- You have at least one tumor that can be biopsied (sampled) to make the study drug, and the biopsy must be done safely.
- You have good overall health (ECOG performance status 0 or 1) and your organs are working well.
- You do not have untreated or unstable brain metastases, active hepatitis B or C, or HIV.
- You are willing to use effective contraception for 6 months after treatment and have no history of severe allergies to certain chemotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.